DOI: http://dx.doi.org/10.22516/25007440.188

Colangiocarcinoma en pacientes con colangitis esclerosante primaria

Camila Andrea Guerrero Bermudez, Mariana Vélez Marín, Juan Carlos Restrepo Gutiérrez

Resumen


La colangitis esclerosante primaria (CEP) es una enfermedad inflamatoria poco común que afecta los conductos biliares produciendo colestasis. Actualmente el único tratamiento disponible es el manejo sintomático con ácido ursodesoxicólico y el trasplante hepático. Además de ser una etiología de cirrosis a largo plazo, en su historia natural tiene una asociación importante con el colangiocarcinoma (CCA), una neoplasia agresiva que es casi exclusiva de este grupo de pacientes y hoy día constituye su principal causa de muerte, debido a que es de difícil diagnóstico y cuenta con opciones muy limitadas de tratamiento.

En el presente artículo se exponen conceptos actuales sobre esta patología enfatizando en la importancia de realizar una adecuada tamización con pruebas diagnósticas efectivas (CA 19-9 y colangioresonancia) que ayuden a diferenciar el CCA de procesos benignos para detectarlo en estadios tempranos donde la probabilidad de tratamiento curativo es mucho mayor.


Palabras clave


Colangitis esclerosante primaria; Colangiocarcinoma; colangiorresonancia

Texto completo:

PDF

Referencias


Sarkar S. Primary Sclerosing Cholangitis Multiple Phenotypes , Multiple Approaches. Clin Liver Dis. 2016;20(1):67–77.

Horsley-Silva JL, Carey EJ, Lindor KD. Advances in primary sclerosing cholangitis. Lancet Gastroenterol Hepatol. 2016;1(1):68–77.

Eaton JE, Talwalkar JA, Lazaridis KN, Gores GJ, Lindor KD. Pathogenesis of Primary Sclerosing Cholangitis and Advances in Diagnosis and Management. Gastroenterology. 2013;145(3):521–36.

Takakura WR, Tabibian JH, Bowlus CL. The evolution of natural history of primary sclerosing cholangitis. Curr Opin Gastroen. 2016;33(2):1.

Gidwaney NG, Pawa S, Das KM. Pathogenesis and clinical spectrum of primary sclerosing cholangitis. World J Gastroentero. 2017 14;23(14):2459.

Boonstra K, Weersma RK, van Erpecum KJ, Rauws EA, Spanier BWM, Poen AC, et al. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology. 2013;58(6):2045–55.

Fevery J, Verslype C. An update on cholangiocarcinoma associated with primary sclerosing cholangitis. Curr Opin Gastroen. 2010;26(3):236–45.

Plentz RR, Malek NP. Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Best Pract Res Clin Gastroenterol. 2015;145(3):521–36.

Rizvi S, Gores GJ. Molecular pathogenesis of cholangiocarcinoma. Dig Dis. 2014;32(5):564–9.

Ehlken H, Zenouzi R, Schramm C. Risk of cholangiocarcinoma in patients with primary sclerosing cholangitis. Curr Opin Gastroen. 2017;33(2):1.

Toy E, Balasubramanian S, Selmi C, Li CS, Bowlus CL. The prevalence, incidence and natural history of primary sclerosing cholangitis in an ethnically diverse population. BMC Gastroenterol. 2011;11(1):83.

Card TR, Solaymani-Dodaran M, West J. Incidence and mortality of primary sclerosing cholangitis in the UK: A population-based cohort study. J Hepatol. 2008;48(6):939–44.

Bergquist A, Ekbom A, Olsson R, Kornfeldt D, Lööf L, Danielsson A, et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol. 2002;36(3):321–7.

Boberg KM, Bergquist A, Mitchell S, Pares A, Rosina F, Broomé U, et al. Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation. Scand J Gastroentero. 2002;37(10):1205–11.

Juran D, Schlicht EM, Andrade M De, Ph D, Konstantinos N. Variations in Primary Sclerosing Cholangitis Across the Age Spectrum. Gastroenterology. 2013;145(3):521–36.

Bergquist A, Seth E Von, Physician R. Best Practice & Research Clinical Gastroenterology Epidemiology of cholangiocarcinoma. Best Pract Res Clin Gastroenterol. 2015;29(2):221–32.

Zheng H, Jiang X. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and in fl ammatory bowel disease : a meta-analysis of 16 observational studies. Eur J Gastroen Hepat. 2016;28(December 2015):383–90.

Rizvi S, Gores GJ. Pathogenesis, Diagnosis, and Management of Cholangiocarcinoma. Gastroenterology. 2013;145(6):1215–29.

Sripa B, Brindley PJ, Mulvenna J, Laha T, Smout MJ, Mairiang E, et al. The tumorigenic liver fluke Opisthorchis viverrini--multiple pathways to cancer. Trends Parasitol. 2012;28(10):395–407.

Sripa B, Bethony JM, Sithithaworn P, Kaewkes S, Mairiang E, Loukas A, et al. Opisthorchiasis and Opisthorchis-associated cholangiocarcinoma in Thailand and Laos. Acta Trop. 2011;120:S158–68.

Young ND, Nagarajan N, Lin SJ, Korhonen PK, Jex AR, Hall RS, et al. The Opisthorchis viverrini genome provides insights into life in the bile duct. Nat Commun. 2014;5:4378.

Aunap. Autoridad nacional de acuicultura y pesca. Gobierno de Colombia. El consumo de pescado en el país va en aumento – Aunap [Internet]. 2017

Pollheimer MJ, Halilbasic E, Fickert P, Hepatology E. Best Practice & Research Clinical Gastroenterology Pathogenesis of primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol. 2017;25(6):727–39.

Liu JZ, Hov JR, Folseraas T, Ellinghaus E, Rushbrook SM, Doncheva NT, et al. Europe PMC Funders Group Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nat Genet. 2013;1(6):670–5.

Williamson K, Chapman R. New Therapeutic Strategies for Primary Sclerosing Cholangitis. Semin Liver Dis. 2016;36(1):005–14.

Thosani N. Endoscopic Retrograde Cholangiopancreatography for Primary Sclerosing Cholangitis Cholangioscopy Choledochoscopy Biliary drainage Bile duct sampling. Clin Liver Dis. 2014;18(4):899–911.

Boberg KM, Lind GE. Best Practice & Research Clinical Gastroenterology Primary sclerosing cholangitis and malignancy. Best Pract Res Clin Gastroenterol. 2017;25(6):753–64.

Folseraas T, Boberg KM. Cancer Risk and Surveillance in Primary Sclerosing Cholangitis. Clin Liver Dis. 2016;20(1):79–98.

Razumilava N, Gores GJ, Lindor KD. Cancer surveillance in patients with primary sclerosing cholangitis. Hepatology. 2011;54(5):1842–52.

Charatcharoenwitthaya P, Enders FB, Halling KC, Lindor KD. Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis. Hepatology. 2008;48(4):1106–17.

Stiehl A, Rudolph G, Klöters-Plachky P, Sauer P, Walker S. Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment. J Hepatol. 2002;36(2):151–6.

Trikudanathan G, Navaneethan U, Njei B, Vargo JJ, Parsi MA. Diagnostic yield of bile duct brushings for cholangiocarcinoma in primary sclerosing cholangitis: a systematic review and meta-analysis. Gastrointesti Endosc. 2014;79(5):783–9.

Rodríguez Martínez R OSG. Salud Uninorte : revista de la División de Ciencias de la Salud, Universidad del Norte. Vol. 29, Revista Salud Uninorte. División de Ciencias dela Salud, Universidad del Norte; 1984. 327-340 p.

Barr Fritcher EG, Kipp BR, Voss JS, Clayton AC, Lindor KD, Halling KC, et al. Primary Sclerosing Cholangitis Patients With Serial Polysomy Fluorescence In Situ Hybridization Results Are at Increased Risk of Cholangiocarcinoma. Am J Gastroenterol. 2011;106(11):2023–8.

Wannhoff A, Hov JR, Folseraas T, Rupp C, Friedrich K, Anmarkrud JA, et al. FUT2 and FUT3 genotype determines CA19-9 cut-off values for detection of cholangiocarcinoma in patients with primary sclerosing cholangitis. J Hepatol. 2017;59(6):1278–84.

Neumann UP, Schmeding M. Role of surgery in cholangiocarcinoma: From resection to transplantation. Best Pr Res Cl Ga. 2015;29(2):295–308.

Ajani JA, Correa AM, Walsh GL, Komaki R, Lee JH, Vaporciyan AA, et al. Trimodality therapy without a platinum compound for localized carcinoma of the esophagus and gastroesophageal junction. Cancer. 2010;116(7):1656–63.

Vogel A, Dudeck O. Is There Any Evidence for a Role of Local Treatment in Cholangiocarcinoma? Viszeralmedizin. 2014;30(4):254–60.

Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B, et al. AASLD PRACTICE GUIDELINES Diagnosis and Management of Primary Sclerosing Cholangitis. 2009;660–78.

Darwish Murad S, Kim WR, Harnois DM, Douglas DD, Burton J, Kulik LM, et al. Efficacy of Neoadjuvant Chemoradiation, Followed by Liver Transplantation, for Perihilar Cholangiocarcinoma at 12 US Centers. Gastroenterology. 2012;143(1):88–98.e3.

Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer. New Engl J Med. 2010;362(14):1273–81.

Okusaka T, Nakachi K, Fukutomi A, Mizuno N, Ohkawa S, Funakoshi A, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Brit J cancer. 2010;103(4):469–74.

André T, Reyes-Vidal JM, Fartoux L, Ross P, Leslie M, Rosmorduc O, et al. Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study. Brit J cancer. 2008;99(6):862–7.

Vogel A, Saborowski A. Cholangiocellular Carcinoma. Digestion [Internet]. 2017;95(3):181–5.

Berretta M, Cavaliere C, Alessandrini L, Stanzione B, Facchini G, Balestreri L, et al. Serum and tissue markers in hepatocellular carcinoma and cholangiocarcinoma: clinical and prognostic implications. Oncotarget. 2017;8(8):14192–220.


Métricas de artículo

Cargando métricas ...

Metrics powered by PLOS ALM

Enlaces refback

  • No hay ningún enlace refback.


Copyright (c) 2018 Revista Colombiana de Gastroenterología

Licencia de Creative Commons
Este obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial-SinObraDerivada 4.0 Internacional.

ISSN versión impresa 0120-9957

ISSN versión en línea 2500-7440

  Licencia de Creative Commons
Los contenidos están protegidos bajo una licencia de Creative Commons Reconocimiento-NoComercial-SinObraDerivada 4.0 Internacional.